ArticleMedicine2026
Association between albumin-corrected anion gap status with all-cause and cardiovascular mortality in individuals with chronic kidney disease: A national retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mortality rate associated with chronic kidney disease (CKD) has been steadily increasing, with disturbances in acid-base balance being a significant factor exacerbating the risk of mortality. Our objective was to evaluate whether the albumin-corrected anion gap (ACAG) status, which reflects acid-base balance, could be used as a mortality risk biomarker for the CKD population in the United States. We conducted a cross-sectional study utilizing the National Health and Nutrition Examination Survey data, collected from 1999 to 2018. Kaplan-Meier curves, weighted Cox regression, restricted cubic spline and subgroup analyses were employed to examine the relation of ACAG with all-cause and cardiovascular mortality in CKD participants. The analysis included a total of 6776 participants. We found a positive relation of ACAG to the mortality risk among CKD participants (all-cause mortality: HR = 1.10, 95% CI = 1.08-1.13, P < .01; cardiovascular mortality: HR = 1.09, 95% CI = 1.04-1.14, P < .01). Subgroup analyses revealed significant interactions between smoking and drinking with regard to the relation between ACAG and mortality in CKD patients. Our research indicates that higher levels of ACAG are related to unfavorable outcomes in CKD. Future research should further explore the role of ACAG and acid-base balance in mortality among CKD patients, as well as investigate potential intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.